Operator
Good day and thank you for standing by. Welcome to the Ironwood Pharmaceuticals First Quarter 2021 Investor Update Call. [Operator Instructions]
I would now like to hand the conference over to your speaker today, Meredith Kaya, Vice President of Finance and Investor Relations. Please go ahead.
Meredith Kaya
Vice President, Finance and Investor Relations
Good morning. And thanks for joining us for our first quarter 2021 investor update. Our press release crossed the wire this morning and can be found on our website.
Today s call and accompanying slides include forward-looking statements. Such statements involve risks and uncertainties that may cause actual results to differ materially. A discussion of these statements and risk factors is available on the current Safe Harbor statement slide as well as under the heading Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2020 and in our future SEC filings. Our forward-looking statements speak
Intellia Therapeutics, Inc. (NASDAQ: NTLA) (before the market open)
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) (before the market open)
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) (before the market open)
Insmed Incorporated (NASDAQ: INSM) (before the market open)
Fulcrum Therapeutics, Inc. (NASDAQ: FULC) (before the market open)
Endo International plc (NASDAQ: ENDP) (before the market open)
Bio-Techne Corporation (NASDAQ: TECH) (before the market open)
Harvard Bioscience, Inc. (NASDAQ: HBIO) (before the market open)
Athenex, Inc. (NASDAQ: ATNX) (before the market open)
Zoetis Inc. (NYSE: ZTS) (before the market open)
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (before the market open)
Syros Pharmaceuticals, Inc. (NASDAQ: SYRS) (before the market open)
Does this report provide customization?
Customization helps organizations gain insight into specific market segments and areas of interest. Therefore,
Market Info Reports provides customized report information according to business needs for strategic calls.
Get Customization of the Report@:
Why Choose Market Info Reports?:
Market Info Reports Research delivers strategic market research reports, industry analysis, statistical surveys and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SME’s, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 600,000 + reports targets high growth emerging markets in the
USA, Europe Middle East, Africa, Asia Pacific covering industries like
Is IRWD Stock A Buy or Sell? yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
/US Irritable Bowel Syndrome Treatment Market Revenue to Cross US$ 1,276.21 Mn in 2027 | Market Seeks to New Posture of Market Trends, Opportunities and Breakthrough Point During 2021-2027
US Irritable Bowel Syndrome Treatment Market Revenue to Cross US$ 1,276.21 Mn in 2027 | Market Seeks to New Posture of Market Trends, Opportunities and Breakthrough Point During 2021-2027
The US irritable bowel syndrome treatment market is expected to reach US$ 1,276.21 Mn in 2027 from US$ 586.61 Mn in 2019. The market is estimated to grow with a CAGR of 10.3% from 2020-2027.
tipApril 12, 2021
Worldwide
US Irritable Bowel Syndrome Treatment Market Analysis to 2027 is a specialized and in-depth study of the